Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic bone marrow transplantation in multiple myeloma.

S Tura1, M Cavo

  • 1University of Bologna, Italy.

Hematology/Oncology Clinics of North America
|April 1, 1992
PubMed
Summary

High-dose chemoradiotherapy with allogeneic stem cell transplant offers a 50-60% remission rate for multiple myeloma (MM). This approach shows improved survival over autologous transplant, despite significant mortality risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

European journal of haematology·2026
Same author

A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide.

Clinical and experimental medicine·2025
Same author

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Journal of cancer research and clinical oncology·2025
Same author

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Journal of bone oncology·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Clinical Presentation and Long-Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study.

Cancer medicine·2024

Area of Science:

  • Hematology
  • Oncology
  • Transplant Immunology

Background:

  • Multiple myeloma (MM) remains largely incurable with conventional chemotherapy.
  • Allogeneic bone marrow transplantation (BMT) has emerged as a potential treatment modality for MM.

Purpose of the Study:

  • To clarify the role and outcomes of high-dose chemoradiotherapy with allogeneic hemopoietic stem cell support for MM.
  • To evaluate the efficacy and safety of allogeneic BMT in MM patients.

Main Methods:

  • Analysis of data from patients treated with high-dose chemoradiotherapy and allogeneic hemopoietic stem cell support.
  • Comparison of outcomes with autologous BMT and conventional chemotherapy.

Main Results:

  • Complete remission rates of 50-60% observed, higher with consolidation therapy.
  • Transplant-related mortality reported at 40-50%.
  • Approximately 40% long-term survival and a 40% 5-year relapse-free survival, exceeding autologous BMT outcomes.

Conclusions:

  • Allogeneic BMT demonstrates a graft-versus-tumor effect in MM, offering potential for long-term survival.
  • Further research is needed to reduce procedure-related morbidity and mortality.
  • Allogeneic BMT should be considered for selected MM patients with poor prognostic factors.

Related Experiment Videos